Q1 results preview: Niche US products, domestic growth may boost pharma biz

Brokerages expect aggregate sales growth of 11 per cent, and 21 per cent earnings growth during this period

Niche products in the US and steady growth in the Indian domestic market are expected to aid earnings growth for pharma players in the first quarter of the current financial year (Q1FY25), according to analysts.

Brokerages expect an aggregate sales growth of 11 per cent and 21 per cent earnings growth during the quarter. Hospitals are expected to post 13 per cent revenue growth with occupancy levels at 65-72 per cent. Analysts at Motilal Oswal said that domestic formulation sales were likely to grow by 10 per cent led by healthy growth in cardiac, gastro, and dermatology therapies that outperformed the